Zacks Research Has Positive Outlook for PBH Q2 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research upped their Q2 2026 EPS estimates for Prestige Consumer Healthcare in a research report issued on Tuesday, September 16th. Zacks Research analyst Team now forecasts that the company will earn $0.99 per share for the quarter, up from their previous forecast of $0.97. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q2 2027 earnings at $1.19 EPS, Q4 2027 earnings at $1.27 EPS and Q1 2028 earnings at $1.27 EPS.

PBH has been the topic of several other reports. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $64.14 on Thursday. The company has a market cap of $3.16 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 2.02 and a beta of 0.46. Prestige Consumer Healthcare has a 52 week low of $61.93 and a 52 week high of $90.04. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The firm’s 50-day simple moving average is $69.34 and its two-hundred day simple moving average is $78.64.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. Prestige Consumer Healthcare’s revenue for the quarter was down 6.6% compared to the same quarter last year. During the same period last year, the company earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC bought a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $84,932,000. Norges Bank bought a new position in Prestige Consumer Healthcare during the second quarter valued at approximately $41,848,000. Invesco Ltd. grew its position in Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after acquiring an additional 261,537 shares during the last quarter. GAMMA Investing LLC grew its position in Prestige Consumer Healthcare by 11,580.3% during the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company’s stock valued at $13,887,000 after acquiring an additional 160,155 shares during the last quarter. Finally, Tributary Capital Management LLC bought a new position in Prestige Consumer Healthcare during the second quarter valued at approximately $11,773,000. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.